Mistletoe-Based Drugs Work in Synergy with Radio-Chemotherapy in the Treatment of Glioma and in Glioblastoma Bearing Mice.

Background: Extracts from (VE) are used in the complementary cancer therapy in Europe for decades. VE contain several compounds like the mistletoe lectins (MLs) 1-3 and viscotoxins and also several minor ingredients. Since mistletoe lectin 1 (ML-1) has been described as the main component of VE harboring antitumor activity, purified native or recombinant ML-1 has been recently used in clinical trials.